AIHA Webinar to Address Fungal Meningitis Control
The Jan. 28, 90-minute presentation will cover ways for compounding pharmacies to prevent employee illnesses and product contamination.
The American Industrial Hygiene Association will present a timely webinar on Jan. 28. Titled , it comes as CDC and states' health authorities are still tracking meningitis and infection cases linked to injections of a contaminated steroid produced by the New England Compounding Center. As of Jan. 14, CDC had tallied 678 cases and 48 deaths, including 14 deaths in Tennessee and 12 in Michigan.
The webinar will last 90 minutes and will begin at noon Eastern time. The presenters will review protective measures, including engineering controls and PPE, to prevent employee illnesses and product contamination. They also will discuss adverse health effects associated with contaminated injectable medications distributed by compounding facilities and the potential causes of contamination. They also will outline the inspection methods to be followed by IH consultants when conducting a site visit at a compounding facility.
The price to attend is $150 for AIHA members and $199 for non-members. The webinar will be archived and available for purchase following the live presentation for an additional $50. (There is $35 post-webinar processing fee for additional individuals participating at a site and seeking CM/COC/Contact Hour credit.)
The presenters are Donald Weekes, CIH, CSP, of InAIR Environmental, Ltd.; Nathaniel Milton, Ph.D., R.Ph, a research advisor in Biopharmaceutical Product Development at Eli Lilly and Company and a registered pharmacist; and Andrew Streifel, MPH, of the University of Minnesota.
Visit this website to register and for more information about the event.